Taurolidine (TLD)
What is Taurolidine (TLD)?
A synthetic broad-spectrum antibiotic with antibacterial, anticoagulant and potential antiangiogenic activities… In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.
Source: National Cancer Institute
This study says: Promising results were obtained with TRD in patients as well. A comprehensive clinical evaluation of TRD is nevertheless missing so far. In one patient with gastric cancer histological remission of the tumor growth was reached. The patient however died from myocardial infarction after occurrence of primary urothelial carcinoma. In stage IV melanoma patients TRD enhanced the tolerability of high-dose interleukin 2.
In two glioblastoma patients TRD was able to significantly improve the quality of life with partial remission of tumor burden. No relevant toxicity was detectable in patients therefore making TRD a promising candidate for further research
This study concluded: The application of taurolidine tends to prevent the development of lung metastases. Furthermore, taurolidine seems to reduce established lung metastases in this in vivo model. Taurolidine may offer additional therapeutic options in patients with colon adenocarcinoma.
Conclusions: The application of taurolidine tends to prevent the development of lung metastases. Furthermore, taurolidine seems to reduce established lung metastases in this in vivo model. Taurolidine may offer additional therapeutic options in patients with colon adenocarcinoma…The application of taurolidine tends to prevent the development of lung metastases and reduces the tumour growth in this in vivo model. Therefore, taurolidine represents an interesting substance for a multimodal approach in the therapy of colon adenocarcinoma even in the case of stages I and II (N0-status), in which adjuvant chemotherapy after the surgical resection is not regularly recommended. Taurolidine may offer additional therapeutic options to prevent or treat lung metastases in the follow-up after surgical resection of colon adenocarcinoma.
This study concluded: Taurolidine is a representative of a novel class of redox-directed, broad-spectrum antineoplastic agents with tumor-selective cytotoxicity. It induces programmed cell death by targeting the oxidative stress response pathway which is compromised in many tumor cells. In initial applications in surgical oncology, Taurolidine i.v. was largely free of significant side-effects and merits further clinical evaluation. Applied perioperatively, Taurolidine promises to reduce circulating tumor cells, a negative predictor for disease-free survival.
Side effects
Over 33 studies have utilized taurolidine intravenously, and no adverse effects apart from vein irritation at high doses have been experienced. To date, taurolidine’s safety profile has been excellent. Allergic reactions have not been observed. Study
Updated September 2024